Study: NCT02228239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine 84 milligram (mg) \[3\*1 of spray in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine 84 milligram (mg) \[3\*1 of spray in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine 84 milligram (mg) \[3\*1 of spray in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine 84 milligram (mg) \[3\*1 of spray in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine 84 milligram (mg) \[3\*1 of spray in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine 84 milligram (mg) \[3\*1 of spray in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Mirtazapine 30 mg capsule will be administered orally on Day 1 in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Mirtazapine 30 mg capsule will be administered orally on Day 1 in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Mirtazapine 30 mg capsule will be administered orally on Day 1 in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Mirtazapine 30 mg capsule will be administered orally on Day 1 in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Mirtazapine 30 mg capsule will be administered orally on Day 1 in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Mirtazapine 30 mg capsule will be administered orally on Day 1 in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matched to Esketamine)
Description: Placebo \[3\*1 in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matched to Esketamine)
Description: Placebo \[3\*1 in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matched to Esketamine)
Description: Placebo \[3\*1 in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matched to Esketamine)
Description: Placebo \[3\*1 in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Matched to Esketamine)
Description: Placebo \[3\*1 in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.